DOK1抗体;DOK1 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: A375 cells, 231 cells, hela cells, Primary antibody: P07261(DOK1 Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

The DOK1 (Docking Protein 1) antibody is a tool used to study the DOK1 protein, a key adaptor molecule involved in signal transduction pathways. DOK1. part of the DOK family (DOK1–7), is characterized by an N-terminal pleckstrin homology (PH) domain, a central phosphotyrosine-binding (PTB) domain, and a C-terminal region with multiple tyrosine phosphorylation sites. It acts downstream of receptor tyrosine kinases (RTKs) and cytokine receptors, mediating interactions with signaling molecules like SHP2. RasGAP, and CSK to regulate cellular processes such as proliferation, differentiation, and apoptosis.

DOK1 is widely expressed in hematopoietic cells and functions as a tumor suppressor by negatively modulating oncogenic signaling. Studies link reduced DOK1 expression to chronic myeloid leukemia (CML), inflammatory disorders, and autoimmune diseases, often due to promoter hypermethylation. Its role in immune regulation includes inhibiting T-cell activation and dampening B-cell receptor signaling, highlighting its importance in maintaining immune homeostasis.

DOK1 antibodies are essential for detecting DOK1 expression, phosphorylation status, and interactions in techniques like Western blotting, immunoprecipitation, and immunohistochemistry. Research using these antibodies has advanced understanding of DOK1’s dual roles in cancer suppression and immune modulation, offering insights into therapeutic strategies targeting DOK1-related pathways in malignancies and immune dysregulation.